Search: onr:"swepub:oai:lup.lub.lu.se:79aa491e-8aa0-4f69-b2d8-f9427ef30dfa" > The role of the pro...
Fältnamn | Indikatorer | Metadata |
---|---|---|
000 | 07264naa a2200853 4500 | |
001 | oai:lup.lub.lu.se:79aa491e-8aa0-4f69-b2d8-f9427ef30dfa | |
003 | SwePub | |
008 | 200423s2015 | |||||||||||000 ||eng| | |
024 | 7 | a https://lup.lub.lu.se/record/79aa491e-8aa0-4f69-b2d8-f9427ef30dfa2 URI |
024 | 7 | a https://doi.org/10.1016/j.urolonc.2015.01.0182 DOI |
040 | a (SwePub)lu | |
041 | a engb eng | |
042 | 9 SwePub | |
072 | 7 | a art2 swepub-publicationtype |
072 | 7 | a ref2 swepub-contenttype |
100 | 1 | a Cremers, Ruben G.u Radboud University Medical Center4 aut |
245 | 1 0 | a The role of the prostate cancer gene 3 urine test in addition to serum prostate-specific antigen level in prostate cancer screening among breast cancer, early-onset gene mutation carriers |
264 | 1 | b Elsevier BV,c 2015 |
520 | a Objective: To evaluate the additive value of the prostate cancer gene 3 (PCA3) urine test to serum prostate-specific antigen (PSA) in prostate cancer (PC) screening among breast cancer, early-onset gene (BRCA) mutation carriers. This study was performed among the Dutch participants of IMPACT, a large international study on the effectiveness of PSA screening among BRCA mutation carriers. Materials and methods: Urinary PCA3 was measured in 191 BRCA1 mutation carriers, 75 BRCA2 mutation carriers, and 308 noncarriers. The physicians and participants were blinded for the results. Serum PSA level≥3.0. ng/ml was used to indicate prostate biopsies. PCA3 was evaluated (1) as an independent indicator for prostate biopsies and (2) as an indicator for prostate biopsies among men with an elevated PSA level. PC detected up to the 2-year screening was used as gold standard as end-of-study biopsies were not performed. Results: Overall, 23 PCs were diagnosed, 20 of which were in men who had an elevated PSA level in the initial screening round. (1) PCA3, successfully determined in 552 participants, was elevated in 188 (cutoff≥25; 34%) or 134 (cutoff≥35; 24%) participants, including 2 of the 3 PCs missed by PSA. PCA3 would have added 157 (≥25; 28%) or 109 (≥35; 20%) biopsy sessions to screening with PSA only. (2) Elevated PCA3 as a requirement for biopsies in addition to PSA would have saved 37 (cutoff≥25) or 43 (cutoff≥35) of the 68 biopsy sessions, and 7 or 11 PCs would have been missed, respectively, including multiple high-risk PCs. So far, PCA3 performed best among BRCA2 mutation carriers, but the numbers are still small. Because PCA3 was not used to indicate prostate biopsies, its true diagnostic value cannot be calculated. Conclusions: The results do not provide evidence for PCA3 as a useful additional indicator of prostate biopsies in BRCA mutation carriers, as many participants had an elevated PCA3 in the absence of PC. This must be interpreted with caution because PCA3 was not used to indicate biopsies. Many participants diagnosed with PC had low PCA3, making it invalid as a restrictive marker for prostate biopsies in men with elevated PSA levels. | |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Cancer och onkologi0 (SwePub)302032 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Cancer and Oncology0 (SwePub)302032 hsv//eng |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Medicinska och farmaceutiska grundvetenskaperx Medicinsk genetik0 (SwePub)301072 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Basic Medicinex Medical Genetics0 (SwePub)301072 hsv//eng |
653 | a BRCA2 | |
653 | a Diagnostic value | |
653 | a Marker | |
653 | a PCA3 | |
653 | a Prostate cancer gene 3 | |
653 | a PSA | |
700 | 1 | a Eeles, Rosalind A.u Institute of Cancer Research London,Royal Marsden NHS Foundation Trust4 aut |
700 | 1 | a Bancroft, E. K.u Institute of Cancer Research London,Royal Marsden NHS Foundation Trust4 aut |
700 | 1 | a Ringelberg-Borsboom, Jannekeu The Netherlands Foundation for the Detection of Hereditary Tumours4 aut |
700 | 1 | a Vasen, Hans F.u The Netherlands Foundation for the Detection of Hereditary Tumours4 aut |
700 | 1 | a Van Asperen, Christi J.u Leiden University Medical Centre4 aut |
700 | 1 | a Schalken, Jack A.u Radboud University Medical Center4 aut |
700 | 1 | a Verhaegh, Gerald W.u Radboud University Medical Center4 aut |
700 | 1 | a Kiemeney, Lambertus A.u Radboud University Medical Center4 aut |
700 | 1 | a Aaronson, N.u Netherlands Cancer Institute4 aut |
700 | 1 | a Ardem-Jones, A.u Royal Marsden NHS Foundation Trust4 aut |
700 | 1 | a Bancroft, E. K.u Royal Marsden NHS Foundation Trust,Institute of Cancer Research London4 aut |
700 | 1 | a Bangma, C.u Erasmus University Medical Center4 aut |
700 | 1 | a Castro, E.u Institute of Cancer Research London,Spanish National Cancer Research Center (CNIO)4 aut |
700 | 1 | a Dearnaley, D.u Institute of Cancer Research London4 aut |
700 | 1 | a Eccles, D.u Princess Anne Hospital4 aut |
700 | 1 | a Eeles, R. A.u Royal Marsden NHS Foundation Trust,Netherlands Cancer Institute4 aut |
700 | 1 | a Evans, D. G.u Manchester University NHS Foundation Trust4 aut |
700 | 1 | a Eyfjord, J.u University of Iceland4 aut |
700 | 1 | a Falconer, A.u Imperial College Healthcare NHS Trust4 aut |
700 | 1 | a Foster, C. S.u HCA Healthcare Laboratories4 aut |
700 | 1 | a Grönberg, H.u Norrland University Hospital4 aut |
700 | 1 | a Hamdy, F. C.u Churchill Hospital,University of Oxford4 aut |
700 | 1 | a Johansson, O.u National University Hospital of Iceland4 aut |
700 | 1 | a Khoo, V.u Royal Marsden NHS Foundation Trust4 aut |
700 | 1 | a Kote-Jarai, Z.u Institute of Cancer Research London4 aut |
700 | 1 | a Lilja, H.u Lund University,Lunds universitet,Klinisk kemi, Malmö,Forskargrupper vid Lunds universitet,Clinical Chemistry, Malmö,Lund University Research Groups,University of Tampere,University of Oxford,Memorial Sloan-Kettering Cancer Center4 aut0 (Swepub:lu)klke-hli |
700 | 1 | a Lubinski, J.u Pomeranian Medical University4 aut |
700 | 1 | a Maehle, L.u Norwegian Radium Hospital4 aut |
700 | 1 | a Melia, J.u University of Cambridge4 aut |
700 | 1 | a Mikropoulos, C.u Institute of Cancer Research London4 aut |
700 | 1 | a Mitchell, G.u University of Melbourne,Peter MacCallum Cancer Centre4 aut |
700 | 1 | a Mitra, A. V.u Institute of Cancer Research London,Royal Free Hospital4 aut |
700 | 1 | a Moss, S.u Queen Mary University4 aut |
700 | 1 | a Moynihan, C.u Institute of Cancer Research London4 aut |
700 | 1 | a Page, E. C.u Institute of Cancer Research London4 aut |
700 | 1 | a Rennert, G.u Carmel Medical Center4 aut |
700 | 1 | a Suri, M.u Nottingham City Hospital4 aut |
700 | 1 | a Wilson, P.u BioZenix4 aut |
710 | 2 | a Radboud University Medical Centerb Institute of Cancer Research London4 org |
710 | 2 | a The IMPACT Steering Committee |
773 | 0 | t Urologic Oncology: Seminars and Original Investigationsd : Elsevier BVg 33:5, s. 19-202q 33:5<19-202x 1078-1439 |
856 | 4 | u http://dx.doi.org/10.1016/j.urolonc.2015.01.018x freey FULLTEXT |
856 | 4 | u https://doi.org/10.1016/j.urolonc.2015.01.018 |
856 | 4 8 | u https://lup.lub.lu.se/record/79aa491e-8aa0-4f69-b2d8-f9427ef30dfa |
856 | 4 8 | u https://doi.org/10.1016/j.urolonc.2015.01.018 |
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.